Home » Authors » Donna Young

Articles by Donna Young

Adnexus Nixes IPO Route, Opts For $430M BMS Exit

Sep. 25, 2007

Pharmaceutical giant Bristol-Myers Squibb Co. is acquiring Waltham-Mass.-based Adnexus Therapeutics Inc. for $430 million in an all-cash deal, the firms said Monday. (BioWorld Today)

Adnexus Nixes IPO Route, Opts For $430M BMS Exit

Sep. 25, 2007

Pharmaceutical giant Bristol-Myers Squibb Co. is acquiring Waltham-Mass.-based Adnexus Therapeutics Inc. for $430 million in an all-cash deal, the firms said Monday. (BioWorld Today)

Senate Joins House In Passing FDA Bill That Renews PDUFA

Sep. 24, 2007

Roche Places Hold On Trial Of Hepatitis Drug From Maxygen

Sep. 24, 2007

Roche Places Hold On Trial Of Hepatitis Drug From Maxygen

Sep. 24, 2007

Senate Joins House In Passing FDA Bill That Renews PDUFA

Sep. 24, 2007

House Passes Long-Awaited Legislation On FDA Reform

Sep. 21, 2007

House Passes Long-Awaited Legislation On FDA Reform

Sep. 21, 2007

Companies, Others Should Plan: Personalized Medicine Coming

Sep. 20, 2007

Companies, Others Should Plan: Personalized Medicine Coming

Sep. 20, 2007

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...